a8877d9c-7dfb-4544-bbb9-7ef4176f3429
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- COAGULATION+0.400
- COMPLEMENT+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_SURFACE+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- MYC_TARGETS_V1-0.500
- G2M_CHECKPOINT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- DNA_REPAIR-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- ADIPOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.900 |
| 2 | TCGA-4Z-AA7N-01A-11R-A39I-07 | — | — | 0.898 |
| 3 | C3L-00412 | — | cohortA1 | 0.896 |
| 4 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.895 |
| 5 | MNG173 | — | — | 0.889 |
| 6 | SRR1316392 | GTEX | — | 0.887 |
| 7 | SRR1346670 | GTEX | — | 0.887 |
| 8 | TCGA-98-A53D-01A-32R-A262-07 | — | cohortMD2 | 0.886 |
| 9 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.885 |
| 10 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |